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Birt-Hogg-Dube´ (BHD) syndrome is a rare inherited genodermatosis characterized by hair follicle hamartomas, kidney
tumors, and spontaneous pneumothorax. Recombination mapping in BHD families delineated the susceptibility locus to
700 kb on chromosome 17p11.2. Protein-truncating mutations were identified in a novel candidate gene in a panel of BHD
families, with a 44% frequency of insertion/deletion mutations within a hypermutable C8 tract. Tissue expression of the
3.8 kb transcript was widespread, including kidney, lung, and skin. The full-length BHD sequence predicted a novel protein,
folliculin, that was highly conserved across species. Discovery of disease-causing mutations in BHD, a novel kidney cancer
gene associated with renal oncocytoma or chromophobe renal cancer, will contribute to understanding the role of folliculin
in pathways common to skin, lung, and kidney development.
Introduction clear cell (CCRC, 75%), (2) papillary (PRC, 15%), (3) oncocytoma
(5%), and (4) chromophobe (5%) (Kovacs et al., 1997). CCRC
develops in patients with inherited von Hippel-Lindau (VHL) dis-Kidney cancer is a major health problem; worldwide, about
150,000 people develop kidney cancer, with 78,000 deaths from ease, a multisystem neoplastic disorder. Mutations in the VHL
tumor suppressor gene are found in the germline of VHL patientsmetastatic disease each year because available treatments are
ineffective (Zbar et al., 2002b). Mutation screening of inherited and in 50% of sporadic CCRC (Latif et al., 1993). The VHL gene
product, pVHL, is involved in the control of hypoxia-induciblekidney cancer genes in affected families allows presymptomatic
diagnosis of family members who are at risk, providing better genes by targeting hypoxia inducible factor-1 (HIF-1) for ubi-
quitin-mediated degradation. Mutational inactivation of VHLpatient prognosis and disease management.
Kidney cancer may be classified into 4 histologic types: (1) leads to the development of highly vascular tumors through
S I G N I F I C A N C E
Studies of families with inherited cancer have revealed tumor suppressor genes and oncogenes that play a major role in the
pathogenesis of human neoplasia. Discovery of protein-truncating mutations in a gene, which occur in patients with BHD and lead
to an increased risk for kidney cancer, represents evidence for a novel gene associated with oncocytoma or chromophobe renal
histology. Biologic significance of the BHD protein, folliculin, is supported by sequence conservation between folliculin and homologs
in mice, Drosophila, and C. elegans, and by mapping studies that suggest that germline mutations in dog and rat BHD homologs
lead to inherited renal cancer. Because BHD is a novel gene, further studies of the BHD protein may lead to the elucidation of novel
mechanisms of tumorigenesis.
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Figure 1. Physical map of the BHD critical region on 17p11.2 defined by critical recombinants in Families 243, 210, and 216 showing location of the putative
BHD gene
A: The BAC tiling path is shown by black horizontal lines with arrowheads indicating directional read of completed sequence and Genbank accession
numbers. BAC overlaps were confirmed by in silico and PCR methods. A single gap was spanned by exons of the COPS3 gene. Locations of polymorphic
markers, shown in red, and genes, shown in blue, were confirmed in silico and by PCR amplification from BAC clones. Telo, telomere; cent, centromere.
B: Critical recombinants identified in Family 243 (D17S2196), Family 210(CA109), and Family 216 (CA138) define the BHD minimal region to 700 kb. Nonrecombin-
ing region is in green.
C: Location of 2 overlapping, uncharacterized mRNAs from melanoma (Genbank accession numbers BC015725 and BC015687) are shown within the 700
kb BHD candidate region. The BHD gene exon/intron structure with 14 coding exons is given.
upregulation of hypoxia-inducible genes (Kondo and Kaelin, families revealed a diagnosis of Birt-Hogg-Dube´ syndrome
(BHD) in 3 of 5 families (Toro et al., 1999).2001).
Hereditary papillary renal carcinoma (HPRC) occurs less We considered whether BHD skin lesions (fibrofolliculomas)
could be used as a marker to identify a novel kidney cancer genefrequently than CCRC and predisposes patients to develop bi-
lateral, multifocal papillary renal tumors (Zbar et al., 1995). Acti- associated with renal oncocytoma. Birt-Hogg-Dube´ syndrome
(BHD) was originally described in a Canadian kindred in 1977vating mutations in the tyrosine kinase domain of the MET proto-
oncogene were found in HPRC Type I (Schmidt et al., 1997, (Birt et al., 1977). Fibrofolliculomas appear as white or skin-
colored papules on the face and upper torso. Histologically,1999), which constitutively phosphorylate and activate the MET
protein (Jeffers et al., 1997). HPRC Type 2 is associated with they are characterized as multiple, anastomosing strands of
proliferating epithelial cells extending from a central hair follicle.inactivating mutations in the fumarate hydratase gene, a Krebs
cycle enzyme, which cause hereditary leiomyoma/renal cell car- Other phenotypic features found to be associated with BHD
included renal neoplasia (Roth et al., 1993; Pavlovich, et al.,cinoma (HLRCC) and multiple cutaneous leiomyoma (MCL)
(TMLC, 2002). 2002), lung cysts, and/or spontaneous pneumothorax (Toro et
al., 1999; Binet et al., 1986). Patients with fibrofolliculomas haveThe cancer-causing genes responsible for renal oncocy-
toma and chromophobe renal carcinoma have not yet been an increased risk for developing renal neoplasms (7-fold) and
spontaneous pneumothorax (50-fold) compared with their unaf-identified. To identify genes involved in the pathogenesis of
renal oncocytoma, 5 families with multiple, bilateral renal onco- fected siblings (Zbar et al., 2002a). In a study of 130 renal
tumors found in 30 BHD patients, the spectrum of renal histologycytomas were identified and clinically evaluated (Weirich et al.,
1998). Interestingly, after noting multiple skin papules (fibrofol- included 34% chromophobe, 5% oncocytoma, 50% chromo-
phobe/oncocytic hybrid, 9% clear cell, and 2% papillary (Pav-liculomas) on the face and neck of a pair of identical twins with
bilateral renal oncocytomas, reevaluation of the oncocytoma lovich et al., 2002).
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ResultsTable 1. BHD gene mutations in a panel of 9 families with BHD syndrome
Family Exon Mutationa Predicted result
Physical map of BHD critical region spans 1.5 Mb and
202 7 1087delAGinsC frameshift, protein truncation defines BHD candidate genes for analysis
228 9 1378→1405dup frameshift, protein truncation
Our previous studies defined the BHD gene locus to a 4 cM174 11 1733insC frameshift, protein truncation
region of chromosome 17p11.2 between D17S1857 and D17S805200 11 1733insC frameshift, protein truncation
210 11 1733insC frameshift, protein truncation by linkage analysis in 9 BHD families. As an initial step in the
216 11 1733insC frameshift, protein truncation positional cloning of the BHD gene, we established a physical
201 11 1733delC frameshift, protein truncation
map of the region of nonrecombination derived from available230 12 C1844G Tyr463X
genomic sequence produced by the large-scale public sequencing
a Mutations are named according to recommendations of the Nomencla- laboratories and Celera. We refined the BAC tiling path map by in
ture System for Human Gene Mutations. The GenBank mRNA sequence
silico methods using BLAST (Altschul et al., 1990) and comparative(AF517523) of BHD is used for reference. The A of the ATG of the initiator
analysis of genome assemblies (UCSC Human Genome Browser,codon is denoted as nt 456. An additional 14 of 53 families had the 1733insC
and 8 of 53 families had the 1733delC. Celera, NCBI, and Ensembl), and identified known genes, unchar-
acterized mRNAs, and spliced EST clusters in the 17p11.2 critical
region (Figure 1A). A PCR-based approach was used to amplify
microsatellites and coding exons of genes to confirm their loca-
tions on overlapping BACs. These results and fluorescence in situWe pursued the identification of renal oncocytoma and chro-
hybridization data (V.M., unpublished data) provided additionalmophobe renal carcinoma genes by taking advantage of the
support for the BAC order. This 1.5 Mb BAC physical map is inphenotypic association of BHD with these histologic types of
agreement with the physical map of Lucas et al. (2001), but dis-renal cancer, and recruited families on the basis of a diagnosis
agrees with the current UCSC Genome Browser (December 2001)of BHD. We performed linkage analysis in 9 BHD families and
and Celera and NCBI (April 2002) genome assemblies.localized the BHD disease locus to a 4 cM region of chromo-
some 17p11.2 between D17S1857 and D17S805 (Schmidt et
High-throughput BHD candidate gene mutation analysisal., 2001), which was confirmed in a Swedish BHD pedigree
is used to evaluate a total of 39 genes, mRNAs, and ESTswith associated renal neoplasms (Khoo et al., 2001). In this
on 17p11.2report, we have used recombination mapping to narrow the
We identified candidate genes from the critical region based onBHD disease locus and identified disease-associated mutations
expressed sequence tag (EST) evidence of expression in skin,in a novel gene which predisposes patients to develop oncocytic
lung, and/or kidney. We determined the exon/intron gene structure,and chromophobe renal tumors, collapsed lung/lung cysts, and
BHD skin lesions. designed intronic primers to amplify coding sequences and splice
Figure 2. Mutation analysis of the BHD gene and
cosegregation with disease in Families 200, 202,
and 230
A: Family 200. a: Sequence analysis of somatic
cell hybrid DNA from a BHD patient shows a C
insertion in the (C)8 tract (nt 1733–1740) within
exon 11 on the affected chromosome and wild-
type (C)8 tract on the unaffected chromosome.
b: The pedigree shows cosegregation of the C
insertion mutation (C9) with disease (blue sym-
bols, affected status). Individual 9 is an asymp-
tomatic mutation carrier who carries the BHD af-
fected haplotype and a history of spontaneous
pneumothorax.
B: Family 202. a: Sequence analysis of subcloned
PCR product from a BHD affected individual
shows the delAGinsC mutation (nt 1087–1088) in
exon 7. b: The mutation produced a unique
DHPLC heteroduplex peak (insert in black sym-
bol) which cosegregated with disease (black
symbols, affected status). Unaffected individuals
(white symbols, unaffected status) show a wild-
type homoduplex DHPLC peak (insert in white
symbol).
C: Family 230. a: Sequence analysis of exon 12 in
BHD affected individuals shows a C→G mutation
(nt 1844) which produces an in-frame terminaton
at codon 463. b: The pedigree shows cosegrega-
tion of the mutation with disease (blue symbols,
affected status).
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Figure 3. Mutation analysis of the BHD gene and
cosegregation with disease in Family 228
A: Sequence analysis of a subcloned PCR prod-
uct from a BHD affected individual shows a 28
bp duplication (nt 1378–1405) in exon 9.
B: The pedigree shows cosegregation of the 28
bp allele with disease (blue symbols, affected
status). PCR products from the exon 9 amplicon
were electrophoresed on a 4%–20% polyacryl-
amide gradient gel to separate the 28 bp dupli-
cation allele (341 bp) from the wild-type allele
(313 bp). Lane 1, 100 bp MW marker; lanes 2, 3,
5, 7, 8, and 9 represent affected individuals (blue
symbols); lanes 4, 6, and 10 represent unaffected
individuals (white symbols); lane 11, water blank.
junctions, and performed high-throughput mutation analysis on a as candidate genes. We analyzed additional BHD families by geno-
typing and haplotype analysis and identified a proximal recombina-panel of patient DNA samples, representing 9 BHD families. Prior
to the identification of the BHD gene (see below), we sequenced tion in BHD Family 216, in the marker CA138, which localized the
BHD gene to a 1.3 Mb region between CA109 and CA138 (Figure321 coding amplicons representing 39 known genes, uncharacter-
ized mRNAs, and spliced EST clusters from the 4 cM region of 1B). Subsequently, we identified a proximal recombination in BHD
Family 243, at D17S2196, which narrowed the BHD critical regionlinkage. This effort identified 129 coding SNPs (single nucleotide
polymorphisms), 49 intronic SNPs, 7 polymorphic repeats (i.e., further to 700 kb (Figure 1B).
poly A tracts), and 6 insertions/deletions. Since no mutations were
identified among these amplicons, we pursued more detailed re- Tissue expression of two overlapping mRNAs from the
combination mapping. BHD critical region suggests a single, potential BHD
candidate gene
Gene mining within the 700 kb critical region using the UCSCAdditional critical recombinants narrow the BHD
candidate gene region to 700 kb Human Genome Browser (December 2001) identified two overlap-
ping, uncharacterized, full-length transcripts from skin melanomaIn parallel with BHD candidate gene sequencing, we developed
13 polymorphic microsatellite markers to look for additional recom- (BC015725 and BC015687). The coding sequences were sup-
ported by additional lung, kidney, and melanoma ESTs (Figurebinants in the region of linkage. Further genotyping and haplotype
analysis of BHD Family 210, described previously (Schmidt et 1C). Since BC015725 and BC015687 mRNAs (1.9 kb and 1.7 kb,
respectively) shared an overlapping coding exon, we consideredal., 2001), identified a recombination in the distal marker CA109,
eliminating genes that were telomeric of CA109 from consideration the possibility that they represented alternatively spliced variants
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Figure 4. RNA tissue expression of BHD and amino
acid sequence of the BHD protein, folliculin
A: Northern blot analysis of BHD expression. A 3.8
kb transcript was detected in all tissues when a
Northern blot (Origene) with 12 major tissues was
hybridized with an exon 11 amplicon of the BHD
gene, representing BC015725. The same size
band was detected on a minor tissue Northern
blot (Origene) which included skin, and a fetal
blot (Clontech) containing lung, kidney, liver,
and brain (data not shown). Hybridization of the
blots with an exon 4 amplicon produced the
same 3.8 kb transcript, representing BC015687
(data not shown). All lanes were loaded with 2
g poly A RNA.
B: Amino acid sequence of the BHD protein, fol-
liculin, consisting of 579 amino acids. The loca-
tions of mutations identified in BHD patients are
underlined in green. The predicted motifs in
black boxes include a conserved SLS potential
phosphorylation site (aa 128–130), a glutamic
acid-rich coil-coil domain (aa 283–313), and an
N-glycosylation site (aa 494–497). Three myristoy-
lation sites are underlined in blue (aa 52–57, aa
266–271, aa 470–475). Regions of high homology
in common in human, mouse, D. melanogaster,
and C. elegans are underlined in black.
of a single gene. We performed Northern blot analysis, using hy- fied in Family 201 which would truncate the protein 38 missense
amino acids downstream. In order to separate the mutant C9 (orbridization probes designed from each mRNA, to determine if they
coded for the same or different transcripts. Hybridization with C7) allele from the wild-type C8 allele for sequence analysis, each
allele was isolated in a somatic cell hybrid (Papadopoulos et al.,probes from either mRNA revealed a 3.8 kb transcript in most
normal adult tissues, including skin, lung, and kidney (Figure 4A), 1995). Sequence analysis of the somatic cell hybrids established
from patients from several of these BHD families confirmed theand in fetal lung, kidney, liver, and brain tissue (data not shown).
The 3.8 kb mRNA transcript size was roughly equal to the sum presence of the (C)9 allele on the affected chromosome 17 and
the (C)8 allele on the wild-type chromosome 17. Cosegregation ofof BC015725 and BC015687 mRNAs, suggesting that these two
transcripts represent splice variants of a single mRNA that is widely these C tract insertion/deletion mutations in BHD-affected haplo-
type carriers was confirmed by sequencing (Figure 2A).expressed. We regarded the novel gene represented by BC015725
and BC015687 mRNAs as an excellent BHD candidate gene based A complex mutation, delAGinsC, which resulted in a frame
shift and predicted protein truncation 11 missense amino acidson the source, tissue expression pattern of the two overlapping
mRNAs, and their location in the 700 kb BHD critical region. downstream, was identified in Family 202 in exon 7 at nt 1087–
1088. This complex mutation was shown to cosegregate with
disease by DHPLC (Figure 2B). The unique DHPLC 2-peak chro-Mutation analysis of the putative BHD gene reveals
frameshift mutations which are predicted matographic profile was produced by separation of hetero-
duplexes, formed between wild-type and mutant allele amplicons,to truncate the protein
The exon/intron structure of the BHD candidate gene represented from homoduplexes (Xiao and Oefner, 2001).
A 28 bp duplication of nt 1378–1405 was found in exon 9 ofby BC015725 and BC015687 was determined, and intronic prim-
ers were designed to amplify coding sequences and splice junc- affected members of BHD Family 228, whose disease phenotype
was previously described (Toro et al., 2002). This resulted in wild-tions from a panel of 9 BHD family probands and 3 unaffected
family members. Sequence analysis of the 14 coding exons con- type and mutant allele size differences that were distinguishable
by electrophoresis of patient-derived amplicons on a 4%–20%tained in these two mRNAs revealed frameshift or termination
mutations in 8 of 9 BHD families on the panel (Table 1). polyacrylamide gel (Figure 3). The mutation created a termination
codon 79 missense amino acids downstream.A cytosine insertion mutation in a mononucleotide (C)8 tract
(nt 1733–1740) in exon 11 was identified in BHD Families 174, A fourth mutation was identified in BHD Family 230, a C to G
at nt 1844, which produced an in-frame termination at codon 463200, 210, and 216, resulting in a frameshift predicted to truncate
the protein 26 missense amino acids downstream. A cytosine in exon 12 (Figure 2C). Each family’s mutation was present in
affected members and asymptomatic BHD haplotype carriersdeletion mutation in the same mononucleotide (C)8 tract was identi-
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within that family, but was absent in noncarriers and at least 160 folliculin is a novel protein. Sequence conservation has been found
normal individuals. in the mouse, D. melanogaster, and C. elegans, underscoring
an important biologic function for the BHD gene in a variety of
Hypermutable mononucleotide C tract in exon 11 organisms. Additional support for the importance of the BHD gene
is mutated in 44% of BHD families tested comes from kidney cancer models in the dog and the rat. Germline
We screened an additional 53 probands from small BHD families mutations in BHD orthologs which map to disease-associated,
for mutations in the mononucleotide (C)8 tract in exon 11 of the syntenic locations in the dog and rat may be responsible for natu-
BHD gene. We found C insertions or deletions in 22 of the 53 rally occurring inherited renal malignancies in these species
probands, suggesting that this cytosine mononucleotide tract is (Jo´nasdo´ttir et al., 2000; Hino et al., 2001).
hypermutable and particularly prone to disease-causing mutations Genes have been identified that cause two of the four main
(Table 1). We have identified a total of 18 (C)9 mutations and 9 histologic types of renal cancer: VHL, responsible for clear cell
(C)7 mutations in 62 BHD patient samples, a (C)8 tract mutation renal carcinoma; MET, responsible for papillary renal carcinoma
frequency of 44%. Insertion/deletion mutations in genes with ho- Type I; and FH, responsible for papillary renal carcinoma Type 2.
monucleotide tracts have been reported in other inherited human This report describes the discovery of the a novel gene with dis-
disorders (Rodenhiser et al., 1996, 1997). A slippage-mediated ease-associated mutations that predispose to the development
mechanism during DNA replication of single base repeats may of kidney tumors with oncocytoma and chromophobe histologies.
result in these frameshift mutations leading to protein truncation How do germline mutations of the BHD gene lead to renal tumors?
(Streisinger et al., 1966). A founder effect/ancestral mutation in The consistent finding of truncating mutations in the BHD gene
this rare disease is an alternative possibility to hypermutability. suggests that the BHD gene might be a tumor suppressor gene.
Loss of heterozygosity studies should address this possibility.
Full length BHD sequence predicts a novel protein, Alternatively, renal tumors may develop by a haploinsufficiency
folliculin, conserved across species mechanism or as a consequence of hypermethylation of the wild-
cDNAs from adult kidney and adult and fetal lung (Clontech) were type BHD allele. Another possibility may be that the inactive BHD
used to amplify 3.2 kb of the BHD transcript and sequenced to4- allele produced by germline mutations results in a dominant-nega-
fold coverage. Separately, a putative full-length clone was obtained tive effect leading to the BHD phenotype.
by screening a normal lung cDNA library (Origene Technologies, Clues to the mechanism of renal tumorigenesis in the BHD
Inc.) and was also sequenced to4-fold coverage. The full-length syndrome may come from consideration of the disease phenotype.
BHD sequence of 3674 nucleotides (AF517523) predicted a pro- The lung cysts and lung collapse (pneumothorax) that are features
tein, folliculin (named for the BHD skin lesion, fibrofolliculoma), with of BHD suggest a defect in a structural protein of the lung wall,
an open reading frame of 579 amino acids (Figure 4B). Programs which may be a component of the cytoskeletal network. The histol-
included in SEQWEB and PROSITE predicted a 64 kDa cyto- ogy of the stroma-rich skin lesions suggests a defect in epithelial-
plasmic protein with a glutamic acid-rich, coil-coil domain, one mesenchymal interaction.
N-glycosylation site, three myristoylation sites, and several casein Renal tumor development in patients affected with BHD is
kinase II and protein kinase C phosphorylation sites. Although unusual. In contrast to other forms of inherited renal cancer in
BLAST alignment against the SwissPro and nonredundant NCBI which affected individuals develop multiple, bilateral renal tumors
protein databases found no significant homology with any known of a specific histologic type, individuals affected with BHD have a
proteins, folliculin was found to be highly conserved across spe- predisposition to develop different histologic types of renal cancer,
cies. Folliculin is 92% identical to the mouse ortholog (MGC 37841 including oncocytoma, chromophobe, and clear cell. Clear cell
gene product, AAH25820), 22%–36% identical (44%–56% posi- renal carcinomas are thought to originate from the proximal renal
tive) to the Drosophila melanogaster ortholog (CG8616 gene prod- tubule, while renal oncocytomas and chromophobe renal carcino-
uct, AAF50597), and 27%–28% identical (44%–52% positive) to mas are thought to originate from the distal renal tubule. All of
the Caenorhabditis elegans ortholog (F22D3.2 gene product, these histologic types may develop within a single kidney of a
AAK31497) by BLASTX (Altschul et al., 1997) and MAST (Bailey BHD-affected individual, suggesting that the BHD mutation affects
and Gribskov, 1998) (data not shown). The homologies across the progenitor cell for both distal and proximal renal tubules. Per-
species suggest an important biological role for folliculin in a wide haps the mutation alters the composition of the extracellular matrix,
range of organisms. producing a structural or microenvironmental abnormality that af-
fects the cells of both the proximal and distal renal tubules, leading
Discussion to uncontrolled cellular proliferation. We anticipate discovery of
novel mechanisms of tumorigenesis through study of this unusual
Using a classic positional cloning strategy, we have identified a
inherited disorder.
gene that plays a critical role in the pathogenesis of an uncommon
form of kidney cancer through its association with the more com- Experimental procedures
mon and clinically detectable phenotype of an inherited disorder
Patient recruitment and samplingof the hair follicle. All mutations discovered in the germline of
Families affected with BHD were recruited and evaluated at the Clinicalaffected members of BHD families were predicted to truncate the
Center, National Institutes of Health, and also on field trips as describedprotein, suggesting a loss-of-function mechanism for phenotype
(Zbar et al., 2002a). Participants in this study provided written informeddevelopment.
consent. The protocol was approved by the NCI-IRB and by the CI-IRB.
Inspection of the predicted amino acid sequence of the BHD
protein, folliculin, and BLAST alignment with available protein data- Development of microsatellites
bases has not disclosed homology to any known gene or gene BLAST of (CA)16, (TATG)8, and (TGC)8 against the BAC genomic sequences
from the region identified di-, tri-, and tetranucleotide tracts. Primers werefamily, or identified key functional domains. This suggests that
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designed to amplify potential polymorphic microsatellites, and markers were
selected with a heterozygosity0.6 in a panel of eight unrelated individuals. Received: July 1, 2002
Primers and PCR conditions are available upon request. Microsatellite geno- Revised: July 23, 2002
typing and haplotype analysis were performed as described (Schmidt et al.,
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